Duyuru • Sep 02
Integral Diagnostics Limited, Annual General Meeting, Oct 31, 2025 Integral Diagnostics Limited, Annual General Meeting, Oct 31, 2025. Duyuru • Mar 11
Private Equity Players Reportedly Keep Close Tabs on Integral Diagnostics Integral Diagnostics Limited (ASX:IDX) is believed once again to be in the spotlight for private equity buyers after its share price took a hit after its half year results, trimming its market value to $837 million. Sources say the diagnostic imaging company is constantly being assessed by private equity firms, eager to increase exposure to healthcare. But right now it is looking like a good buying opportunity and is grabbing attention. Obvious suitors would be the underbidders from the sale last year of the Healius diagnostic imaging group that sold for $965 million to Affinity Equity Partners. The underbidders were TPG Capital, L.P. and Pacific Equity Partners. Duyuru • Feb 05
Integral Diagnostics Limited Appoints Manish Mittal to the Board as Radiologist Executive Director Integral Diagnostics Limited announced the appointment of experienced IDX radiologist Dr. Manish Mittal (MBBS (Hons), MD, FRCR, FRANZCR, FSCMR) to the Board as a Radiologist Executive Director with effect from 5 February 2025. Mittal is a Fellow of both the UK and Australia & New Zealand Royal Colleges of Radiology with a professional focus on MRI, including musculoskeletal, prostrate and cardiac imaging in addition to extensive experience in neuroradiology and abdominal radiology. Dr. Mittal has worked within IDX and its precursor businesses for over 18 years and held senior clinical governance and leadership roles across a number of IDX business units. He is currently the Clinical Director of IDXt, IDX's fast growing teleradiology business, and also a consultant radiologist at Gold Coast University Hospital. Duyuru • Jan 20
Integral Diagnostics Limited Announces Company Secretary Changes In accordance with Listing Rule 3.16, Integral Diagnostics Limited announced that effective 20 January 2025, Mr. John Merity has been appointed as company's permanent Company Secretary, continuing from the interim role to which he was appointed on 7 June 2024. Also effective from 20 January 2025, Ms Nikki Dalla Valle will relinquish her role as Company Secretary, continuing in her role as General Counsel, responsible for Legal and Risk. Duyuru • Dec 20
Integral Diagnostics Limited Announces Board Appointments Integral Diagnostics Limited has appointed the following Capitol Directors to the Integral Board with effect from 20 December 2024. Laura McBain, as Non-Executive Director; and Dr Kevin Shaw, as Non-Executive Director. Ms McBain has extensive executive and leadership experience having held roles as Managing Director at Bellamy's Australia, Maggie Beer Holdings and Lark Distilling. Dr Shaw is a highly qualified radiologist with fellowship training in MRI. He is the Director of Medical Imaging at University Hospital Geelong. Duyuru • Dec 12
Integral Diagnostics Limited (ASX:IDX) completed the acquisition of Capitol Health Limited (ASX:CAJ). Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million on June 17, 2024. The consideration consists of common equity of Integral Diagnostics Limited at a ratio of 0.12849 per common equity of Capitol Health Limited. As per the transaction, Integral and Capitol shareholders would be expected to own approximately 63% and 37% respectively of the combined entity. The transaction is subject to approval by regulatory board / committee, approval of merger agreement by target board, approval of offer by target shareholders, due diligence investigation and subject to court approval. As of October 29, 2024, Capitol announces that the Federal Court of Australia (Court) has today made orders to postpone the date of the Scheme Meeting at which Capitol Shareholders will vote on the proposed Scheme. The Scheme Meeting has been postponed from October 31, 2024 to December 2, 2024. The date for the Second Court Hearing has been changed from November 1, 2024 to December 4, 2024. As a consequence of the Court orders postponing the Scheme Meeting, the indicative Effective Date on which the Scheme comes into effect and is binding on Capitol Shareholders will be on December 5, 2024. As of November 25, 2024, the Scheme is subject to a number of conditions precedent, including that IDX has received informal merger clearance from the Australian Competition and Consumer Commission (ACCC). The ACCC has delayed its proposed decision date in relation to the Competition Approval to allow the ACCC to consider the divestment. The ACCC has not yet announced a new proposed date of its decision in relation to the Competition Approval, although Capitol anticipates that the decision date will occur in December 2024. The Scheme Meeting will proceed on December 2, 2024. As of December 10, 2024, the Australian Competition and Consumer Commission confirmed that it will not oppose the merger and the Federal Court of Australia made orders approving the Scheme. The deal is expected to complete on December 11, 2024.
Barrenjoey Capital Partners and Jefferies (Australia) Pty Ltd acted as financial advisors to Integral Diagnostics Limited (ASX:IDX) while Citigroup Global Markets Australia Pty Limited acted as a financial advisor to Capitol Health Limited. Herbert Smith Freehills acted as a legal advisor to Integral Diagnostics Limited while Maddocks Inc. Pty Ltd. provided legal assistance to Capitol Health Limited. KPMG Financial Advisory Services (Australia) Pty Limited provided fairness opinion in the deal to Capitol Health Limited. Computershare Investor Services Pty Limited acted as registrar to Integral Diagnostics Limited and Capitol Health Limited.
Integral Diagnostics Limited (ASX:IDX) completed the acquisition of Capitol Health Limited (ASX:CAJ) on December 11, 2024. Duyuru • Jun 19
Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million. Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million on June 17, 2024. The consideration consists of common equity of Integral Diagnostics Limited at a ratio of 0.12849 per common equity of Capitol Health Limited. As per the transaction, Integral and Capitol shareholders would be expected to own
approximately 63% and 37% respectively of the combined entity. The transaction is subject to approval by regulatory board / committee, approval of merger agreement by target board, approval of offer by target shareholders, due diligence investigation and subject to court approval. Barrenjoey Capital Partners and Jefferies (Australia) Pty Ltd acted as financial advisors and Herbert Smith Freehills acted as legal advisor to Integral Diagnostics Limited. Citigroup Global Markets Australia Pty Limited acted as financial advisor and Maddocks Inc. Pty Ltd. acted as legal advisor to Capitol Health Limited. Duyuru • Feb 07
IDX™ Announces Appointment of Scott Paterson as Worldwide CFO IDX™ announced the appointment of industry veteran Scott Paterson as chief financial officer. In his role, Paterson will partner with Worldwide CEO Myles Peacock and the IDX Board of Directors to continue the growth and evolution of the business. Paterson has held various senior finance roles for over 15 years, with many spent in marketing content, communications and technology. Prior to joining IDX, Paterson was CFO of private equity-backed TREND Networks, where he played a key role in the growth of the organization. He subsequently led the business through a private equity exit. Prior to TREND Networks, Paterson was group financial controller at Guinness World Records, where he was integral in transforming the business from its publishing core to a more diversified media enterprise focused on content creation and both digital and broadcast media. Paterson’s appointment is effective immediately. Duyuru • Dec 12
Integral Diagnostics Limited Announces Change of Company Secretary Integral Diagnostics Limited advised that Kirsty Lally has resigned as Company Secretary of Integral Diagnostics Limited effective 14 December 2023. Nikki Dalla Valle has been appointed as Company Secretary effective 14 December 2023 and is the person nominated under Listing Rule 12.6 for communication with ASX in relation to Listing Rule matters. Duyuru • Nov 30
Integral Diagnostics Limited Announces Resignation of Helen Kurincic as Director Effective 29 November 2023 Integral Diagnostics Limited announced resignation of Helen Kurincic as director effective 29 November 2023. Duyuru • Sep 28
Integral Diagnostics Limited Appoints Toby Hall as Director Integral Diagnostics Limited announced that the appointment of Toby Hall as director. The date of appointment is September 28, 2023. Duyuru • Sep 25
Integral Diagnostics Limited Declares Fully Franked Final Dividend for the Six Months Ended June 30, 2023, Payable on October 04, 2023 Integral Diagnostics Limited declared a fully franked final dividend of AUD 0.03500000 per ordinary share for the six months ended June 30, 2023 with a record date of 1 September 2023. Ex date of August 31, 2023.Payable on 4 October 2023. Duyuru • Aug 28
Integral Diagnostics Limited Declares Fully Franked Final Dividend, Payable on October 04, 2023 On 28 August 2023 the directors of Integral Diagnostics Limited declared a fully franked final dividend of 3.5 cents per ordinary share with a record date of 1 September 2023 to be paid on 4 October 2023. Duyuru • Aug 10
Integral Diagnostics Limited Announces Board Changes Integral Diagnostics Limited announced the appointment of Ingrid Player as an independent non-executive Director, effective 29 August 2023. Ms. Player has more than 20 years' experience in the healthcare industry, gained from leadership roles across the private, public and not for profit sectors. In her executive career, Ms. Player was Group Executive - Legal, Governance and Sustainability at Healthscope. As a qualified lawyer, she previously worked in private legal practice in Australia and Europe specialising in corporate law, M&A and capital markets. She brings to the Board extensive experience in leveraging corporate transactions and major capital projects to achieve strategic outcomes, as well as skills in risk management, government relations, sustainability and corporate governance. She currently serves as a Non-Executive Director of Cleanaway Management Ltd, Cogstate Ltd, Epworth Foundation and HealthShare Victoria. She holds a Bachelor of Laws (Hons) and Bachelor of Economics from Monash University and is a member of the AICD. She will be appointed a Member of the Audit, Risk & Compliance Committee and a Member of the People, Culture & Remuneration Committee. The company announced the resignation of John Atkin as an independent non-executive Director effective 31 August 2023. The company also announced the resignation of Dr. Nazar Bokani, an Executive Radiologist Director effective 9 August 2023. Dr. Bokani joined the Board on 26 April 2021 and is relocating overseas to be closer to his family. Duyuru • Feb 18
Integral Diagnostics Limited Announces Ordinary Dividend for the Six Months Ended December 31, 2022, Payable on April 4, 2023 Integral Diagnostics Limited announced an ordinary dividend of AUD 0.025000 for the six months ended December 31, 2022. The ex-date is March 2, 2023, record date is March 3, 2023, and payment date is April 4, 2023. Duyuru • Feb 16
Integral Diagnostics Limited to Report First Half, 2023 Results on Feb 17, 2023 Integral Diagnostics Limited announced that they will report first half, 2023 results on Feb 17, 2023 Duyuru • Jan 09
Integral Diagnostics Limited, Annual General Meeting, Nov 03, 2023 Integral Diagnostics Limited, Annual General Meeting, Nov 03, 2023. 
